|
Motor Neuron DiseasesTable of Contents (click to jump to sections)What are Motor Neuron Diseases? Is there any treatment? What is the prognosis? What research is being done? Organizations Publicaciones en Español What are Motor Neuron Diseases? The motor neuron diseases (MNDs) are a group of progressive neurological disorders that destroy cells that control essential muscle activity such as speaking, walking, breathing, and swallowing. Normally, messages from nerve cells in the brain (called upper motor neurons) are transmitted to nerve cells in the brain stem and spinal cord (called lower motor neurons) and from them to particular muscles. When there are disruptions in these signals, the result can be gradual muscle weakening, wasting away, and uncontrollable twitching (called fasciculations). Eventually, the ability to control voluntary movement can be lost. MNDs may be inherited or acquired, and they occur in all age groups. In adults, symptoms often appear after age 40. In children, particularly in inherited or familial forms of the disease, symptoms can be present at birth or appear before the child learns to walk. The causes of sporadic (noninherited) MNDs are not known, but environmental, toxic, viral, or genetic factors may be implicated. Common MNDs include amyotrophic lateral sclerosis (ALS), progressive bulbar palsy, primary lateral sclerosis, and progressive muscular atrophy. Other MNDs include the many inherited forms of spinal muscular atrophy and post-polio syndrome, a condition that can strike polio survivors decades after their recovery from poliomyelitis. Is there any treatment? There is no cure or standard treatment for the MNDs. Symptomatic and supportive treatment can help patients be more comfortable
while maintaining their quality of life. The drug riluzole (Rilutek®), which as of this date is the only drug approved by
the U.S. Food and Drug Administration to treat ALS, prolongs life by 2-3 months but does not relieve symptoms. Other medicines
that may help reduce symptoms include muscle relaxants such as baclofen, tizanidine, and the benzodiazepines for spasticity;
glycopyrrolate and atropine to reduce the flow of saliva; quinine or phenytoin for cramps; anticonvulsants and nonsteroidal
anti-inflammatory drugs to relieve pain; tranquilizers to help with sleeping problems; antidepressants; and botulinum toxin,
amitriptyline, and other anticholinergic drugs to control drooling. Some patients may require stronger medicines such as
morphine to cope with musculoskeletal abnormalities or pain in later stages of the disorders, and opiates are used to provide
comfort care in terminal stages of the disease.
Physical and speech therapy, occupational therapy, and rehabilitation may help to improve posture, prevent joint immobility,
slow muscle weakness and atrophy, and cope with swallowing difficulties. Applying heat may relieve muscle pain. Assistive
devices such as supports or braces, orthotics, speech synthesizers, and wheelchairs help some patients retain independence.
What is the prognosis? Prognosis varies depending on the type of MND and the age of onset. Some MNDs, such as primary lateral sclerosis, are not
fatal and progress slowly. Patients with spinal muscular atrophy may appear to be stable for long periods, but improvement
should not be expected. Some MNDs, such as ALS and some forms of spinal muscular atrophy, are fatal.
What research is being done? Select this link to view a list of studies currently seeking patients.
Prepared by: NINDS health-related material is provided for information purposes only and does not necessarily represent endorsement by or an official position of the National Institute of Neurological Disorders and Stroke or any other Federal agency. Advice on the treatment or care of an individual patient should be obtained through consultation with a physician who has examined that patient or is familiar with that patient's medical history. All NINDS-prepared information is in the public domain and may be freely copied. Credit to the NINDS or the NIH is appreciated. Last updated July 25, 2007 This information has been provided by The National Institute of Neurological Disorders and Stroke (NINDS). |